Analyzing hematological indices and clinical associations of FLT3 mutation in acute leukemia

Kiran Aamir; Farhan Ahmed Shaikh; Azhar Ali; Durga Devi; Kiran Memon; Sidrah Sidrah; Aamir Ramzan; Naila Memon

doi:10.53730/ijhs.v7nS1.14377

Authors

Kiran Aamir
drkiran73@yahoo.com
Associate Professor, Pathology Department, Liaquat University of Medical and Health Sciences Jamshoro Hyderabad
Farhan Ahmed Shaikh Lecturer, Consultant Haematologist, Pathology Department, Bilawal Medical College for Boys, Liaquat University of Medical and Health Sciences Jamshoro Hyderabad
Azhar Ali Assistant Professor in Pathology Department at Jhalwan Medical College Khuzdar, Balochistan
Durga Devi Lecturer in Pathology Department, Bilawal Medical College for Boys, Liaquat University of Medical and Health Sciences Jamshoro Hyderabad
Kiran Memon Assistant Professor in Pathology Department, Indus Medical College, Tando Muhammad Khan
Sidrah Resident Histopathology, Lecturer in Bilawal Medical College for Boys Liaquat University of Medical and Health Sciences Jamshoro Hyderabad
Aamir Ramzan Lecturer in pathology Department Liaquat University of Medical and Health Sciences Jamshoro Hyderabad
Naila Memon Senior WMO, Consultant Physician, Liaquat University Hospital Hyderabad

Keywords:

Hematological Indices, Clinical Correlates, Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL)

Abstract

Objective: The purpose of this research is to examine the relationship between FLT3 mutation and hematological indices and clinical correlates in patients with severe myelogenous leukemia & acute lymphoblastic leukemia. Study Design: Descriptive Study. Place and Duration: Diagnostic and research Laboratory Liaquat university of Medical and health sciences jamshoro Hyderabad. January 2021 to December 2021. Methods: Total 79 cases of acute leukemia were included in this study. Patients provided written consent for detailed demographics and for self-structure questionnaire. All the data was obtained from laboratory records. The patients' clinico-hematologic and immunophenotypic characteristics were recorded, and the FLT3 mutation was analyzed molecularly. SPSS 24.0 was used to analyze all data. Results: Majority of the patients 44 (55.7%) were males and 35 (44.3%) cases were females. The included patients had mean age 37.21±14.59 years and had mean BMI 23.6±4.18 kg/m². We found that 48 (60.8%) cases had acute myeloid leukemia (AML) and 31 (39.2%) cases had acute lymphoblastic leukemia (ALL). Frequency of FLT 3 mutations in AML patients was 6 (12.5%) and in ALL patients was 1 (3.2%) after polymerase chain reaction. WBC was the most statistically significant hematological and clinical result connected with FLT3 mutation.

Downloads

Download data is not yet available.

References

Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141:1117‐1134.

Rosnet O, Schiff C, Pebusque MJ, et al. Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood. 1993;82:1110‐1119

Hannum C, Culpepper J, Campbell D, et al. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature. 1994;368:643‐648

Drexler HG, Meyer C, Quentmeier H. Effects of FLT3 ligand on proliferation and survival of myeloid leukemia cells. Leuk Lymphoma. 1999;33:83‐91

Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 1996;10:1911‐1918

Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001;97:2434‐2439

Swerdlow, S.H.; Campo, E.; Harris, N.L.; Jaffe, E.S.; Pileri, S.A.; STEIN, H.; Thiele, J.; Vardiman, J.W. WHO classification of tumours of haematopoietic and lymphoid tissues 4.ed. Geneva: WHO Press, 2008. 439p.

Koh, Y. ; Park, J.; Ahn, K.S.; Kim, I.; Bang, S.M.; Lee, J.H.; Yoon, S.S.; Lee, D.S.; Lee, Y.Y.; Park, S.; Kim, B.K. Different clinical importance of FLT3 internal tandem duplications in aml according to FAB classification: possible existence of distinct leukemogenesis involving monocyte differentiation pathway. Ann. Hematol, v.88, n.11, p.1089-1097, 2009.

Nakao M Yokota S Iwai T et al Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.Leukemia.10199619111918

Kiyoi H Naoe T NakanoY et al Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.Blood.93199930743080

Iwai T Yokota S Nakao M et al Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia: the Children's Cancer and Leukemia Study Group, Japan.Leukemia.1319993843

Kiyoi H Towatari M Yokota S et al Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product.Leukemia.12199813331337

Mizuki M Fenski R Halfter H et al Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the ras and STAT5 pathways.Blood.96200039073914

Iwai T Yokota S Nakao M et al Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia. The Children's Cancer and Leukemia Study Group, Japan.Leukemia.1319993843

Yamamoto Y Kiyoi H Nakano Y et al Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.Blood.97200124342439

Yohe S. Molecular Genetic Markers in Acute Myeloid Leukemia. J Clin Med. 2015;4(3):460–478.

Ivey A, Hills RK, Simpson MA, Grech GA, Patel GY, Bhudia N, et al. UK National Cancer Research Institute AML Working Group. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016;374(5):422–433.

Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the productKiyoi H, Towatari M, Yokota S, Hamaguchi M, Ohno R, Saito H, et al. Leukemia.1998;12:1333-1337.

Acute myeloid leukemia-FAB classification and its correlation with clinico-haematological featuresHassan K, Qureshi M, Shafi S, Ikram N, Akhtar MJ. J Pak Med Assoc.1993;43:200-203.

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trialsKottaridis Panagiotis D., Gale Rosemary E., Frew Marion E., Harrison Georgina, Langabeer Stephen E., Belton Andrea A., Walker Helen, Wheatley Keith, Bowen David T., Burnett Alan K., Goldstone Anthony H., Linch David C.. Blood.2001;98(6).

FLT3 length mutations in AML: correlation to cytogenetics, FAB-subtype, and prognosis in 652 patients Schnittger S, Schoch C, Kern W, et al. Blood.2000;96:826a.

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosisThiede Christian, Steudel Christine, Mohr Brigitte, Schaich Markus, Schäkel Ulrike, Platzbecker Uwe, Wermke Martin, Bornhäuser Martin, Ritter Markus, Neubauer Andreas, Ehninger Gerhard, Illmer Thomas. Blood.2002;99(12).

Varma, N.; Varma, S. Proliferative indices, cytogenetics, immunophenotye and other prognostic parameters in myelodysplastic syndromes. Indian J. Pathol. Microbiol., v.51, n.1, p.97-101, 2008.

Wang, W.; Wang, X.Q.; Xu, X.P.; Lin, G.W. Prevalence and prognostic significance of FLT3 gene mutations in patients with acute leukaemia: analysis of patients from the Shanghai Leukaemia Cooperative Group. J. Int. Med. Res, v.38, n.2, p.432-442, 2010.

Liu, H.; Yu, H.; Jia, H.Y.; Zhang, W.; GUO, C.J. Detection of FLT3 gene mutation in hematologic malignancies and its clinical significance. Zhongguo Shi Yan Xue Ye Xue Za Zhi, v.15, n.4, p.709-713, 2007.

Zhu, H-H.; Liu, Y-R.; Jiang, H.; Lu, J.; Qin, Y-Z.; Jiang, Q.; Bao, L.; Ruan, G-R.; Jiang, B.; Huang, X. CD34 expression on bone marrow blasts is a novel predictor of poor prognosis independent of FlT3-ITD in acute myeloid leukemia with the NPM1-mutation. Leukemia Res., v.37, n.1, p.624-630, 2013.

Barragán, E.; Montesinos, P.; Camos, M.; González, M.; Calasanz, M.J.; Román-Gómez, J.; Gómez-Casares, M.T.; Ayala, R.; López, J.; Fuster, Ó.; Colomer, D.; Chillón, C.; Larrayoz, M.J.; Sánchez-Godoy, P.; González-Campos, J.; Manso, F.; Amador, M.L.; Vellenga, E.; Lowenberg, B.; Sanz, M.A. Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy. Haematologica, v.96, n.10, p.1470-1477, 2011.

Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemiaKiyoi H, Naoe T, Nakano Y, et al. Blood .1997;93:3074-3080.

Kiyoi H, Kawashima N, Ishikawa Y. FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development. Cancer Sci. 2020 Feb;111(2):312-322. doi: 10.1111/cas.14274. Epub 2019 Dec 30. PMID: 31821677; PMCID: PMC7004512.

Mahmood R, Altaf C, Malik HS, Khan SA. Clinico-Haematologic association and prognostic relevance of NPM1 and FLT3-ITD mutations in acute Myeloid Leukaemia. Pak J Med Sci. 2019 Jan-Feb;35(1):23-28. doi: 10.12669/pjms.35.1.285. PMID: 30881390; PMCID: PMC6408656.